American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.

摘要

In late 2005, MethylGene Inc reported the initiation of a phase I/II clinical trial to assess the histone deacetylase (HDAC) inhibitor MGCD-0103 (MethylGene Inc/Pharmion Corp/Taiho Pharmaceutical Co Ltd) in combination with the DNA methyltransferase inhibitor azacitidine in patients with advanced myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Guillermo Garcia-Manero (MD Anderson Cancer Center, USA) and colleagues presented results from the phase I portion of the clinical trial. This ongoing trial recruited 23 patients, 18 with AML and 5 with MDS, to receive 35, 60, 90, 110 or 135 mg of MGCD-0103 orally three times weekly (n = 3, 3, 8, 6 and 3, respectively; first dose on day 5 of the first cycle) plus 75 mg/m2/day of azacitidine subcutaneously for the first 7 days of each 28-day treatment cycle. At the time of this meeting, six of these patients were still being dosed, and one patient with AML had completed seven cycles.